Article Figures & Data
Figures
- FIG 1
The Kaplan-Meier cumulative acquisition rates of infection according to the modified intention-to-treat analysis. (Adapted from reference 28 with permission of the publisher.) Rather than representing “an anomalous nonlinear increase in acquisition in the placebo group in the first year of the trial” (4), the yellow ellipse highlights the midpoints between the 6-month and 12-month visits for the placebo recipients and vaccine recipients who became infected during the first 6 to 12 months of the trial.
- FIG 2
Estimated cumulative HIV-1 incidence curves from placebo recipients and from vaccine recipients with low, medium, and high IgG antibody responses showing specific binding to the V1V2CaseA2-gp70 fusion protein. (Adapted from reference 19 with permission of the publisher.)
